AI Article Synopsis

  • Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer with a historically low 5-year survival rate, but this study looked at long-term local-regional recurrence (LRR) in non-metastatic IBC patients treated at one institution.
  • The research analyzed data from 262 patients who underwent trimodal therapy (neoadjuvant chemotherapy, modified radical mastectomy, and adjuvant radiation), with significant findings on recurrence and survival outcomes.
  • Results showed a 6.9% local-regional recurrence rate, indicating treatment effectiveness, and those achieving a pathologic complete response had significantly better disease-free and overall survival rates.

Article Abstract

Background: Inflammatory breast cancer (IBC) represents a rare (2-3 %) but aggressive subset of breast cancer with a historically reported 5-year overall survival rate of 50 % and a 3-year local-regional recurrence (LRR) rate of 20 %. This study aimed to evaluate long-term LRR in a contemporary cohort of non-metastatic IBC patients undergoing trimodal therapy at a single institution and identify factors associated with local and distant failure.

Methods: The study identified 262 patients with non-metastatic IBC who received trimodal therapy (neoadjuvant chemotherapy, modified radical mastectomy, adjuvant radiation) from an institutional prospective database (2007-2019). Long-term outcomes of local-regional and distant metastasis were reported. Survival outcomes were analyzed using the Cox proportional hazards regression model.

Results: The median age at diagnosis was 52 years, and the median follow-up period was 5.1 years. In this cohort, 82 (31.3 %) patients achieved a pathologic complete response (pCR) in the breast and axilla. Local-regional recurrence was observed in 18 (6.9 %) patients (11 isolated to the chest wall, 4 isolated to regional nodes, and 3 involving chest wall and ipsilateral axillary nodes). Distant metastasis was observed in 92 (35.1 %) patients. During the follow-up period, 90 deaths occurred. In the multivariate analysis, pCR was associated with improved disease-free survival (hazard ratio [HR], 0.26; 95 % confidence interval [CI], 0.13-0.51; p = 0.001) and overall survival (HR, 0.31; 95 % CI, 0.15-0.65; p = 002).

Conclusions: During a median follow-up period longer than 5 years, the local-regional relapse rate for the IBC patients treated with contemporary trimodal therapy was 6.9%, similar to that for the non-IBC patients. After chemotherapy, surgical resection with modified radical mastectomy to negative margins and postmastectomy radiation therapy resulted in excellent long-term local-regional control.

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-023-13906-5DOI Listing

Publication Analysis

Top Keywords

trimodal therapy
16
local-regional recurrence
12
breast cancer
12
follow-up period
12
inflammatory breast
8
patients
8
contemporary trimodal
8
non-metastatic ibc
8
ibc patients
8
modified radical
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!